BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Paternoster S, Falasca M. Dissecting the Physiology and Pathophysiology of Glucagon-Like Peptide-1. Front Endocrinol (Lausanne) 2018;9:584. [PMID: 30364192 DOI: 10.3389/fendo.2018.00584] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 6.0] [Reference Citation Analysis]
Number Citing Articles
1 Hanchard J, Capó-Vélez CM, Deusch K, Lidington D, Bolz SS. Stabilizing Cellular Barriers: Raising the Shields Against COVID-19. Front Endocrinol (Lausanne) 2020;11:583006. [PMID: 33101215 DOI: 10.3389/fendo.2020.583006] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Lian J, Casari I, Falasca M. Modulatory role of the endocannabinoidome in the pathophysiology of the gastrointestinal tract. Pharmacol Res 2021;175:106025. [PMID: 34883211 DOI: 10.1016/j.phrs.2021.106025] [Reference Citation Analysis]
3 Texada MJ, Koyama T, Rewitz K. Regulation of Body Size and Growth Control. Genetics 2020;216:269-313. [PMID: 33023929 DOI: 10.1534/genetics.120.303095] [Cited by in Crossref: 22] [Cited by in F6Publishing: 10] [Article Influence: 22.0] [Reference Citation Analysis]
4 Korfhage J, Skinner ME, Basu J, Greenson JK, Miller RA, Lombard DB. Canagliflozin increases intestinal adenoma burden in female Apc Min/+ mice. J Gerontol A Biol Sci Med Sci 2021:glab254. [PMID: 34448851 DOI: 10.1093/gerona/glab254] [Reference Citation Analysis]
5 Brierley DI, de Lartigue G. Reappraising the role of the vagus nerve in GLP-1-mediated regulation of eating. Br J Pharmacol 2021. [PMID: 34185884 DOI: 10.1111/bph.15603] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
6 Lamontagne-Proulx J, Coulombe K, Dahhani F, Côté M, Guyaz C, Tremblay C, Di Marzo V, Flamand N, Calon F, Soulet D. Effect of Docosahexaenoic Acid (DHA) at the Enteric Level in a Synucleinopathy Mouse Model. Nutrients 2021;13:4218. [PMID: 34959768 DOI: 10.3390/nu13124218] [Reference Citation Analysis]
7 Cremonini E, Daveri E, Mastaloudis A, Oteiza PI. (-)-Epicatechin and Anthocyanins Modulate GLP-1 Metabolism: Evidence from C57BL/6J Mice and GLUTag Cells. J Nutr 2021;151:1497-506. [PMID: 33693759 DOI: 10.1093/jn/nxab029] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
8 Lang S, Wei R, Wei T, Gu L, Feng J, Yan H, Yang J, Hong T. Glucagon receptor antagonism promotes the production of gut proglucagon-derived peptides in diabetic mice. Peptides 2020;131:170349. [DOI: 10.1016/j.peptides.2020.170349] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
9 Xie SZ, Yang G, Jiang XM, Qin DY, Li QM, Zha XQ, Pan LH, Jin CS, Luo JP. Polygonatum cyrtonema Hua Polysaccharide Promotes GLP-1 Secretion from Enteroendocrine L-Cells through Sweet Taste Receptor-Mediated cAMP Signaling. J Agric Food Chem 2020;68:6864-72. [PMID: 32456438 DOI: 10.1021/acs.jafc.0c02058] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
10 Tomas A, Jones B, Leech C. New Insights into Beta-Cell GLP-1 Receptor and cAMP Signaling. J Mol Biol 2020;432:1347-66. [PMID: 31446075 DOI: 10.1016/j.jmb.2019.08.009] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 5.7] [Reference Citation Analysis]
11 Chou WL. Therapeutic potential of targeting intestinal bitter taste receptors in diabetes associated with dyslipidemia. Pharmacol Res 2021;170:105693. [PMID: 34048925 DOI: 10.1016/j.phrs.2021.105693] [Reference Citation Analysis]
12 Le Gléau L, Rouault C, Osinski C, Prifti E, Soula HA, Debédat J, Busieau P, Amouyal C, Clément K, Andreelli F, Ribeiro A, Serradas P. Intestinal alteration of α-gustducin and sweet taste signaling pathway in metabolic diseases is partly rescued after weight loss and diabetes remission. Am J Physiol Endocrinol Metab 2021;321:E417-32. [PMID: 34338041 DOI: 10.1152/ajpendo.00071.2021] [Reference Citation Analysis]
13 Kabahizi A, Wallace B, Lieu L, Chau D, Dong Y, Hwang ES, Williams KW. Glucagon-like peptide-1 (GLP-1) signalling in the brain: From neural circuits and metabolism to therapeutics. Br J Pharmacol 2021. [PMID: 34519026 DOI: 10.1111/bph.15682] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
14 Nagase C, Tanno M, Kouzu H, Miki T, Nishida J, Murakami N, Kokubu N, Nagano N, Nishikawa R, Yoshioka N, Hasegawa T, Kita H, Tsuchida A, Ohnishi H, Miura T. Reduction in GLP-1 secretory capacity may be a novel independent risk factor of coronary artery stenosis. Sci Rep 2021;11:15578. [PMID: 34341424 DOI: 10.1038/s41598-021-95065-9] [Reference Citation Analysis]
15 Glossmann HH, Lutz OMD. Pharmacology of metformin - An update. Eur J Pharmacol 2019;865:172782. [PMID: 31705902 DOI: 10.1016/j.ejphar.2019.172782] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 5.3] [Reference Citation Analysis]
16 Okai CA, Wölter M, Russ M, Koy C, Petre BA, Rath W, Pecks U, Glocker MO. Profiling of intact blood proteins by matrix-assisted laser desorption/ionization mass spectrometry without the need for freezing - Dried serum spots as future clinical tools for patient screening. Rapid Commun Mass Spectrom 2021;35:e9121. [PMID: 33955049 DOI: 10.1002/rcm.9121] [Reference Citation Analysis]
17 Morrow NM, Hanson AA, Mulvihill EE. Distinct Identity of GLP-1R, GLP-2R, and GIPR Expressing Cells and Signaling Circuits Within the Gastrointestinal Tract. Front Cell Dev Biol 2021;9:703966. [PMID: 34660576 DOI: 10.3389/fcell.2021.703966] [Reference Citation Analysis]
18 Paternoster S, Simpson PV, Kokh E, Kizilkaya HS, Rosenkilde MM, Mancera RL, Keating DJ, Massi M, Falasca M. Pharmacological and structure-activity relationship studies of oleoyl-lysophosphatidylinositol synthetic mimetics. Pharmacol Res 2021;172:105822. [PMID: 34411732 DOI: 10.1016/j.phrs.2021.105822] [Reference Citation Analysis]
19 García-Carro C, Vergara A, Agraz I, Jacobs-Cachá C, Espinel E, Seron D, Soler MJ. The New Era for Reno-Cardiovascular Treatment in Type 2 Diabetes. J Clin Med 2019;8:E864. [PMID: 31212945 DOI: 10.3390/jcm8060864] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
20 Savych A, Bilyk O, Vaschuk V, Humeniuk I. Analysis of inulin and fructans in Taraxacum officinale L. roots as the main inulin-containing component of antidiabetic herbal mixture. PHAR 2021;68:527-32. [DOI: 10.3897/pharmacia.68.e66266] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
21 Zhang J, Chen Y, Wang J, Xia H, Zheng Y. The effect of liraglutide on insulin allergy in a patient with glucocorticoid-induced diabetes and multiple sclerosis. Nagoya J Med Sci 2021;83:343-51. [PMID: 34239182 DOI: 10.18999/nagjms.83.2.343] [Reference Citation Analysis]
22 Savych A, Marchyshyn S, Kozyr H, Yarema N. Determination of inulin in the herbal mixtures by GC-MS method. PHAR 2021;68:181-7. [DOI: 10.3897/pharmacia.68.e55051] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 5.0] [Reference Citation Analysis]
23 Jalleh R, Pham H, Marathe CS, Wu T, Buttfield MD, Hatzinikolas S, Malbert CH, Rigda RS, Lange K, Trahair LG, Feinle-Bisset C, Rayner CK, Horowitz M, Jones KL. Acute Effects of Lixisenatide on Energy Intake in Healthy Subjects and Patients with Type 2 Diabetes: Relationship to Gastric Emptying and Intragastric Distribution. Nutrients 2020;12:E1962. [PMID: 32630191 DOI: 10.3390/nu12071962] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
24 He Y, Chen Z, Nie X, Wang D, Zhang Q, Peng T, Zhang C, Wu D, Zhang J. Recent advances in polysaccharides from edible and medicinal Polygonati rhizoma: From bench to market. Int J Biol Macromol 2022;195:102-16. [PMID: 34896461 DOI: 10.1016/j.ijbiomac.2021.12.010] [Reference Citation Analysis]
25 Tveter KM, Villa-Rodriguez JA, Cabales AJ, Zhang L, Bawagan FG, Duran RM, Roopchand DE. Polyphenol-induced improvements in glucose metabolism are associated with bile acid signaling to intestinal farnesoid X receptor. BMJ Open Diabetes Res Care 2020;8:e001386. [PMID: 32771984 DOI: 10.1136/bmjdrc-2020-001386] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 4.0] [Reference Citation Analysis]
26 Lang S, Yang J, Yang K, Gu L, Cui X, Wei T, Liu J, Le Y, Wang H, Wei R, Hong T. Glucagon receptor antagonist upregulates circulating GLP-1 level by promoting intestinal L-cell proliferation and GLP-1 production in type 2 diabetes. BMJ Open Diabetes Res Care. 2020;8:e001025. [PMID: 32139602 DOI: 10.1136/bmjdrc-2019-001025] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 3.5] [Reference Citation Analysis]
27 Mikov M, Pavlović N, Stanimirov B, Đanić M, Goločorbin-Kon S, Stankov K, Al-Salami H. DPP-4 Inhibitors: Renoprotective Potential and Pharmacokinetics in Type 2 Diabetes Mellitus Patients with Renal Impairment. Eur J Drug Metab Pharmacokinet 2020;45:1-14. [PMID: 31385198 DOI: 10.1007/s13318-019-00570-y] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]